All In Biotech

Drug Trial Radar · NCT06746311

This is a Phase 1 Study in Which Healthy Volunteers and Participants With Chronic HBV Infection Will be Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of HT-101 Injection in Healthy Subjects and Patients With Chronic Hepatitis B Virus Infection: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Doses, and Dose Escalation Phase 1 Clinical Study

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

82

Actual

Start

Nov 22, 2022

Primary completion

May 13, 2024

Study completion Jun 17, 2024

Sponsor

Sponsor type
Industry
First posted
Dec 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase 1 Study of HT-101 in Healthy Subjects and Patients With Chronic Hepatitis B The trial consisted of two components. Part A involved a single ascending dose study where healthy participants were administered one dose of HT-101 or placebo subcutaneously (SC). Part B involved a multiple ascending dose study where participants with chronic hepatitis B virus infection were administered two dose of HT-101 or placebo every 4 weeks subcutaneously (SC).

Conditions

  • Chronic Hepatitis b

Interventions

  • HT-101Drug

    Single dose of HT-101 administered subcutaneously.

  • HT-101Drug

    Multiple dose of HT-101 administered subcutaneously.

  • PlaceboDrug

    Placebo, containing no active ingredient, administered subcutaneouly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: From enrollment to the end of treatment at 24 weeks
  2. Clinically significant abnormalitiesTime frame: From enrollment to the end of treatment at 24 weeks

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Ditan Hospital Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Friendship Hospital

    Beijing, Beijing Municipality, China

  • Nanfang Hospital

    Guangzhou, Guangdong, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • The First Bethune Hospital of Jilin University

    Changchun, Jilin, China

  • Yanbian University Hospital

    Yanji, Jilin, China

  • Shanghai Public Health Clinical Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.